Cipla invests $100 million in InvaGen operations
after close1 source ↓written by the desknot a recommendation
- in Cipla EU
- $100 million investment
- and a profit
- $3.76 cr
- as of March
- $0.60 cr
Cipla's board approved a $100 million investment in Cipla (EU) Limited, aimed at supporting InvaGen Pharmaceuticals. The funds will cover capital expenditure, working capital, and general corporate needs. This move underscores Cipla's strategy to enhance its international operations and manufacturing capabilities. 💼
The investment reflects a commitment to strengthen its global presence, with Cipla (EU) Limited reporting a turnover of $3.76 cr and a profit of $0.60 cr as of March 2025.
Not investment advice. For informational purposes only.